In pre-market trading activity, AZZ Inc (NYSE:AZZ) experienced a notable increase in its share price following the disclosure of its financial results for the third quarter. The company reported adjusted earnings of $1.52 per share, exceeding the consensus estimate of $1.47 per share. Additionally, AZZ posted revenues amounting to $425.746 million, which surpassed analyst forecasts set at $418.164 million. The market responded to these results with AZZ shares climbing 2.1%, reaching $112.09 in pre-market transactions.
The encouraging financial performance of AZZ contrasts with a broader spectrum of stock activities in pre-market trading where various companies experienced significant shifts driven by discrete corporate developments. Several stocks recorded strong gains. Among them, CIMG Inc (NASDAQ:IMG) surged by 33.3%, with its shares hitting $1.44 after disclosing the acquisition of approximately $124 million in commercial contracts related to computing power.
Another substantial pre-market gainer was ECD Automotive Design Inc (NASDAQ:ECDA), whose stock advanced 26.4% to $0.59. This movement follows news that the company is in ongoing discussions with a lender regarding potential strategic transactions valued within a range of $2 million to $10 million.
Acrivon Therapeutics Inc (NASDAQ:ACRV) saw a 22.1% rise in its share price, trading at $3.60 after announcing plans to deliver clinical updates on its Phase 2b studies and forthcoming confirmatory Phase 3 trial for the investigational agent ACR-368. The company also indicated that it would present initial clinical data on ACR-2316 and further developments in its AP3 pipeline on January 8.
Other notable pre-market gainers include Nuvve Holding Corp (NASDAQ:NVVE), which advanced 17.1% to $4.11 following a substantial 60% increase in the previous session. RenovoRx Inc (NASDAQ:RNXT) jumped 16.8% to $1.18, while Serina Therapeutics Inc (NYSE:SER) increased 16.4% to $2.82 after a 15% gain on the prior trading day.
Super League Enterprise Inc (NASDAQ:SLE) climbed 11.2% to $0.68 after entering into an asset purchase agreement with Let's Bounce, announced on January 5. Regencell Bioscience Holdings Ltd (NASDAQ:RGC) continued its upward trend with a 7.7% pre-market gain to $56.87, extending its 60% rise from the day before. Additionally, defense industry heavyweight Northrop Grumman Corp (NYSE:NOC) posted a 6.8% rise, reaching $616.26, possibly influenced by recent remarks from former President Trump regarding plans to increase the 2027 military budget from one trillion to $1.5 trillion.
Conversely, several equities experienced downturns in pre-market trading. Immuneering Corp (NASDAQ:IMRX) declined sharply by 20.7% to $6.61 after reporting updated survival and safety data from its ongoing Phase 2a trial evaluating atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow-up time.
Erasca Inc (NASDAQ:ERAS) dropped 14% to $4.45 after achieving a 42% surge in the previous session. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) closed lower by 13.7% to $15.60 following the pricing announcement of a $130 million public offering involving common stock and pre-funded warrants.
Other pre-market losers included Oriental Culture Holding Ltd (NASDAQ:OCG), which retreated 10.2% to $0.021, Australian Oilseeds Holdings Ltd (NASDAQ:COOT) which declined 9.4% to $0.71 after a prior 29% gain, and Sky Quarry Inc (NASDAQ:SKYQ) whose shares fell 9.4% to $0.62 following an 18% rise previously.
Similarly, FBS Global Ltd (NASDAQ:FBGL) saw a 9.3% decrease to $0.78, continuing its downward movement from a 5% decline the prior day. United Microelectronics Corp (NYSE:UMC) slipped 6.3% to $8.37 despite its 10% increase after reporting year-end sales growth. Cyclerion Therapeutics Inc (NASDAQ:CYCN) dropped 6.1% to $1.69, extending a previous 8% decline, and Revolution Medicines Inc (NASDAQ:RVMD) fell 6% to $96.57 amid reports denying ongoing discussions with AbbVie.
These developments illustrate a volatile pre-market environment with stocks reacting sensitively to clinical trial data, financing news, and defense sector budgetary prospects. AZZ's ability to outperform expectations and signal revenue strength contributes positively to its share price momentum, while the diverse performance across other securities indicates varied market responses to corporate news flow and sector-specific catalysts.